Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X‐linked protoporphyria
Autor: | Robert J. Desnick, Herbert L. Bonkovsky, D. Montgomery Bissell, Manisha Balwani, Joseph R. Bloomer, Hetanshi Naik, Jessica Overbey, Karl E. Anderson, Bruce Wang, John D. Phillips, Ashwani K. Singal |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
Research Report
Patient-Reported Outcomes Measurement Information System Pediatrics medicine.medical_specialty erythropoietic proto lcsh:QH426-470 Endocrinology Diabetes and Metabolism Hospital Anxiety and Depression Scale Biochemistry Genetics and Molecular Biology (miscellaneous) lcsh:Diseases of the endocrine glands. Clinical endocrinology porphyria PROMIS 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Disease severity Quality of life Internal Medicine Medicine 030212 general & internal medicine Depression (differential diagnoses) lcsh:RC648-665 business.industry Research Reports medicine.disease 3. Good health lcsh:Genetics Porphyria quality of life Anxiety Erythropoietic protoporphyria medicine.symptom business |
Zdroj: | JIMD Reports, Vol 50, Iss 1, Pp 9-19 (2019) JIMD Reports JIMD reports, vol 50, iss 1 |
ISSN: | 2192-8312 |
Popis: | Author(s): Naik, Hetanshi; Overbey, Jessica R; Desnick, Robert J; Anderson, Karl E; Bissell, D Montgomery; Bloomer, Joseph; Bonkovsky, Herbert L; Phillips, John D; Wang, Bruce; Singal, Ashwani; Balwani, Manisha | Abstract: BackgroundErythropoietic protoporphyria (EPP) and X-linked Protoporphyria (XLP) are rare photodermatoses presenting with severe phototoxicity. Although anecdotally, providers who treat EPP patients acknowledge their life-altering effects, tools that fully capture their impact on quality of life (QoL) are lacking.MethodsAdult patients with EPP/XLP were given four validated QoL tools: the Patient Reported Outcomes Measurement Information System 57 (PROMIS-57), the Hospital Anxiety and Depression Scale (HADS), the Illness Perception Questionnaire Revised (IPQR), and an EPP-Specific tool. All patients received the PROMIS-57 while the HADS, IPQR, and EPP-Specific tools were introduced at a later date. Associations between responses and clinical phenotypes were explored.ResultsTwo hundred and two patients were included; 193 completed PROMIS-57, 104 completed IPQR, 103 completed HADS, and 107 completed the EPP-Specific tool. The IPQR showed that patients strongly believed EPP/XLP had a negative impact on their lives. Mean scores in anxiety and depression domains of both HADS and PROMIS-57 were normal; however, anxiety scores from HADS were borderline/abnormal in 20% of patients. The EPP-Specific tool revealed a decreased QoL in most patients. The PROMIS-57 showed that 21.8% of patients have clinically significant pain interference. Several tool domains correlated with measures of disease severity, most being from the PROMIS-57.ConclusionsImpaired QoL is an important consequence of EPP/XLP. PROMIS-57 was most sensitive in evaluating impaired QoL in EPP/XLP. Further research is needed to compare the effectiveness of it for assessing response to treatment. |
Databáze: | OpenAIRE |
Externí odkaz: |